Improving treatment options for advanced hormone receptor-positive breast cancer
Integrative subtyping to improve therapeutic options for metastatic hormone receptor-positive breast cancer
This study is looking at how different types of hormone receptor-positive breast cancer that has spread respond to treatments, so that doctors can create personalized therapy plans based on the unique genetic features of each patient's tumor.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10911175 on NIH RePORTER |
What this research studies
This research investigates how different subtypes of metastatic hormone receptor-positive breast cancer respond to treatments. By analyzing genomic data from early-stage tumors, the study aims to identify specific characteristics of these subtypes that could inform personalized therapy options. The research will utilize advanced bioinformatics and multi-omic data analysis to understand the behavior of these cancer subtypes after they have metastasized. Patients may have the opportunity to benefit from tailored treatment strategies based on their tumor's unique genetic profile.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with metastatic hormone receptor-positive breast cancer.
Not a fit: Patients with non-hormone receptor-positive breast cancer or those at earlier stages of the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with metastatic hormone receptor-positive breast cancer.
How similar studies have performed: Previous research has shown promise in using genomic profiling to tailor cancer treatments, suggesting that this approach could yield significant insights.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Caswell-Jin, Jennifer — Stanford University
- Study coordinator: Caswell-Jin, Jennifer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.